Premium
Angiotensin I‐Converting Enzyme And Metabolism Of The Haematological Peptide N ‐Acetyl‐Seryl‐Aspartyl‐Lysyl‐Proline
Author(s) -
Azizi Michel,
Junot Christophe,
Ezan Eric,
Ménard Joël
Publication year - 2001
Publication title -
clinical and experimental pharmacology and physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 103
eISSN - 1440-1681
pISSN - 0305-1870
DOI - 10.1046/j.1440-1681.2001.03560.x
Subject(s) - chemistry , angiotensin converting enzyme , renin–angiotensin system , ace inhibitor , in vivo , medicine , endocrinology , tetrapeptide , enzyme , peptide , biochemistry , biology , microbiology and biotechnology , blood pressure
SUMMARY 1. Angiotensin I‐converting enzyme (ACE) has two homologous active N‐ and C‐terminal domains and displays activity towards a broad range of substrates. The tetrapeptide N ‐acetyl‐seryl‐aspartyl‐lysyl‐proline (AcSDKP) has been shown to be hydrolysed in vitro by ACE and to be a preferential substrate for its N‐terminal active site. This peptide reversibly prevents the recruitment of pluripotent haematopoietic stem cells and normal early progenitors into the S‐phase. 2. Angiotensin I‐converting enzyme inhibitors, given as a single dose to normal subjects or during long‐term treatment in hypertensive patients, result in plasma AcSDKP levels five‐ to six‐fold higher and urine concentrations 40‐fold higher than those of control subjects and/or patients. Thus, AcSDKP is a natural peptide hydrolysed by the N‐terminal domain of ACE in vivo . In addition, ACE may be implicated in the process of haematopoietic stem cell regulation by permanently degrading this natural circulating inhibitor of cell entry into the S‐phase. 3. Besides hydrolysis by ACE, the second very effective mechanism by which AcSDKP is cleared from plasma is glomerular filtration. Because of its high sensitivity and specificity, the measurement of AcSDKP in plasma and urine provides a valuable tool in screening specific inhibitors of the N‐terminal domain of ACE and in monitoring ACE inhibition during chronic treatment. 4. The long‐term consequences of AcSDKP accumulation are not known. During chronic ACE inhibition in rats, AcSDKP levels slightly increase in organs with high ACE content (kidneys, lungs). To significantly increase its concentration in target haematopoietic organs (the extracellular fraction of bone marrow), AcSDKP has to be infused on top of a captopril‐based treatment. 5. A selective inhibitor of the N‐domain of ACE in vitro and in vivo has been identified recently. The phosphinic peptide RXP 407 does not interfere with blood pressure regulation, but does increase, dose dependently, plasma concentrations of AcSDKP in mice, in contrast with lisinopril, which affects the metabolism of both AcSDKP and angiotensin I. N‐Terminal‐selective ACE inhibitors may be used to selectively control AcSDKP metabolism in target haematopoietic organs. This new therapeutic strategy may be of value for protecting haematopoietic cells from the toxicity of cancer chemotherapy.